SEARCH:   Advanced

Blood, Vol. 110, Issue 9, 3291-3300, November 1, 2007 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma Blood Jenner et al. 110: 3291 Supplemental materials for: Jenner et al Files in this Data Supplement: Table S1. Transcripts in regions of LOH of regions of 16q with differential expression in comparison with cases without LOH (PDF, 80.1 KB) - Cases are grouped according to the region of LOH: region 1 (all of 16q), region 2 (16q12.1) or region 3 (16q21-16q24.1). Only those genes located within the region of LOH with significantly altered expression in cases with LOH are tabulated, see text. Table S2. Low-CYLD and -WWOX signatures (PDF, 122 KB) - (A) Low-CYLD signature: the 73 probe sets common to cases with low-CYLD expression in the study data set and the independent data set. (B) Low-WWOX signature: the 71 probe sets common to cases with low-CYLD expression in the study data set and the independent data set. Table S3. Low-WWOX signature (PDF, 58.7 KB) - The 71 probe sets common to cases with low-CYLD expression in the study data set and the independent data set. * Fold change is shown as low versus high quartile. A negative change means the expression was lower in the low-WWOX samples. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020